Medpace (NASDAQ: MEDP) director sells 5,000 shares outside plan

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) director Brian T. Carley reported selling 5,000 shares of Medpace common stock on 2026-08-19 in an open-market or private transaction at a weighted average price of $608.63 per share, with individual trades ranging from $608.30 to $609.62. After this transaction, Carley directly holds 27,825 shares of Medpace common stock. The filing indicates the transaction was not made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 5,000 shares

Net Sell 1 txn

Insider Carley Brian T

Role Director

Sold 5,000 shs ($3.04M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	5,000	$608.63	$3.04M

Holdings After Transaction: Common Stock — 27,825 shares (Direct)

Footnotes (1)

1. F1. The reported price is a weighted average price. The shares were sold in multiple transactions ranging from $608.30 to $609.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Key Figures

Shares sold: 5,000 shares Weighted average sale price: $608.63 per share Sale price range: $608.30–$609.62 per share +2 more

5 metrics

Shares sold 5,000 shares Common Stock sale on 2026-08-19 by director Brian T. Carley

Weighted average sale price $608.63 per share Sale of 5,000 Medpace common shares on 2026-08-19

Sale price range $608.30–$609.62 per share Price range for multiple transactions included in the 5,000-share sale

Shares held after transaction 27,825 shares Direct holdings of Brian T. Carley after the 5,000-share sale

Rule 10b5-1 status Not under Rule 10b5-1 plan Document-level 10b5-1 checkbox not marked as affirmed

Key Terms

weighted average price, Rule 10b5-1, open market or private transaction

3 terms

weighted average price financial

"The reported price is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Rule 10b5-1 regulatory

"The filing indicates the transaction was not made under a Rule 10b5-1 trading plan."

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction financial

"transaction_code_description: Sale in open market or private transaction"

FAQ

What insider transaction did MEDP director Brian T. Carley report?

Brian T. Carley reported a sale of 5,000 MEDP common shares on 2026-08-19 in an open-market or private transaction, according to the Form 4.

At what price did Brian T. Carley sell Medpace (MEDP) shares?

Carley sold the shares at a weighted average price of $608.63 per MEDP share, with individual trade prices ranging from $608.30 to $609.62, as disclosed in the Form 4 footnote.

How many Medpace (MEDP) shares does Brian T. Carley own after this sale?

After the reported sale, Brian T. Carley directly owns 27,825 shares of Medpace common stock, based on the Form 4 disclosure.

Was Brian T. Carley’s MEDP share sale under a Rule 10b5-1 plan?

No. The Form 4’s Rule 10b5-1 checkbox is not checked, indicating the 5,000-share sale was not reported as being made under a Rule 10b5-1 trading plan.

What does the price range in Brian T. Carley’s MEDP sale mean?

The footnote states the reported $608.63 is a weighted average price for multiple trades executed between $608.30 and $609.62; detailed trade prices and sizes are available from the reporting person upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 04:12 PM Accepted by SEC EDGAR 08/21/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carley Brian T

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S		5,000	D	$608.63(1)	27,825	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported price is a weighted average price. The shares were sold in multiple transactions ranging from $608.30 to $609.62. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

	/s/ Stephen P. Ewald, Attorney-in-Fact for Brian T. Carley	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)